NCT03304639

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

CompletedPHASE2INTERVENTIONAL

Trial Details

Start: 2018-06-12Est. Completion: 2022-06-07

Enrollment target: 9 participants

Locations

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
Anchorage Oncology Centre, Anchorage, Alaska, United States
Katmai Oncology Group, Anchorage, Alaska, United States
Providence Alaska Medical Center, Anchorage, Alaska, United States
Banner University Medical Center - Tucson, Tucson, Arizona, United States
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
PCR Oncology, Arroyo Grande, California, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States
Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States

Other microbiome trials you might be interested in

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP TrialPhase 3Recruiting

Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients …

Birmingham, United StatesEst. completion Dec 31, 2026

View Trial →

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)Phase 1Recruiting

Advanced Or Metastatic Merkel Cell Carcinoma

This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to…

Tampa, United StatesEst. completion Apr 2027

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.